Plenary Keynote Sessions


MONDAY, AUGUST 14, 2023 | 4:20-5:30 PM

SOLVING TODAY’S CHALLENGES

Current and Future Trends in Biomanufacturing of New Modalities
Konstantin B. KonstantinovKonstantin B. Konstantinov, PhD, CTO, Codiak Biosciences


Commercializing Gene Therapies – The Power of Patient Advocacy
Rachel SalzmanRachel Salzman, DVM, Founder, The Stop ALD Foundation & Executive Vice President, Portfolio, External Affairs & Development, Alcyone Therapeutics


WEDNESDAY, AUGUST 16, 2023 | 3:50-5:00 PM

LEADING TO TOMORROW’S ADVANCES

The Digitalization of Biomanufacturing
Richard D. BraatzRichard D. Braatz, PhD, Edwin R. Gilliland Professor, Chemical Engineering, Massachusetts Institute of Technology


Overcoming Current Challenges in Bioprocessing
Jerry A. MurryJerry A. Murry, PhD, Senior Vice President, Process Development, Amgen



SPEAKER BIOGRAPHIES

Richard D. Braatz, PhD, Edwin R. Gilliland Professor, Chemical Engineering, Massachusetts Institute of Technology
Dr. Richard D. Braatz is the Edwin R. Gilliland Professor at the Massachusetts Institute of Technology (MIT). He leads the modeling, control, and systems activities in many biopharmaceutical manufacturing efforts at MIT, including for vaccines, gene therapy, and monoclonal antibodies. Most activities are in automated process development workflows and modeling, design, and control of fully automated modular manufacturing unit operations and end-to-end systems, which are experimentally validated. He has consulted or collaborated with more than 25 companies including Novartis, Pfizer, Merck, Biogen, Sanofi, and Amgen. Honors include the AIChE PD2M Award for Outstanding Contribution to QbD for Drug Substance, the AIChE Separation Division Innovation Award, the AIChE Excellence in Process Development Research Award, the Research Collaboration Award from the Council for Chemical Research, and the IEEE Control Systems Society Transition to Practice Award. He is a member of the National Academy of Engineering.

Konstantin B. Konstantinov, PhD, CTO, Codiak Biosciences
Before joining Codiak, Konstantin Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub, including all functions, from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, California for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer-reviewed papers and has more than 15 patents and patent applications. During the last 23 years, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he has pioneered the development of an end-to-end integrated continuous biomanufacturing platform, which is becoming a strategic technological trend for the biomanufacturing industry worldwide. Dr. Konstantinov received his PhD in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware. He is a member of the board of directors for Repligen.

Jerry A. Murry, PhD, Senior Vice President, Process Development, Amgen
Jerry Murry is senior vice president, Process Development. Murry has held several roles at Amgen, including vice president of Small Molecule Process & Product Development, vice president of Chemistry, Manufacturing & Controls Lifecycle Management, and, most recently, vice president of Drug Product Technologies. Prior to Amgen, Murry spent six years at Merck Research and the preceding six years at Pfizer Central Research. Earlier, he was a National Institutes of Health (NIH) fellow at Harvard University. Murry received his bachelor’s degree in biochemistry from Texas Lutheran University and earned his PhD in chemistry from the University of Utah.

Rachel Salzman, DVM, Founder, The Stop ALD Foundation & Executive Vice President, Portfolio, External Affairs & Development, Alcyone Therapeutics
Longstanding advocate for patients, families, and caregivers impacted by ALD and AMN with experience advancing therapies for these conditions. Dr. Rachel Salzman is a passionate advocate for advancing therapies where novel platforms such as genetic and cellular therapies hold promise. Dr. Salzman co-founded SwanBio Therapeutics in 2017, after serving as a leadership member of The Stop ALD Foundation since 2001. For over 15 years she has provided drug development advice to biopharmaceutical executives working in the rare disease space where complex biological and business issues intersect with serious unmet medical need. The Stop ALD Foundation is a non-profit Medical Research Organization dedicated to employing entrepreneurial approaches and innovative methodology towards effective therapies, cures, and prevention of X-linked adrenoleukodystrophy (ALD), an often-fatal neurodegenerative disease. Dr. Salzman received a DVM (Doctor of Veterinary Medicine) from Oklahoma State University and a BS in Animal Science from Rutgers University.